Where do we land on GLP-1s after three years of normalization?
When Ozempic hit cultural saturation in 2023, the discourse was 99% "is this a miracle weight-loss drug" and 1% "what are the long-term effects." We've now had enough time for the second question to start producing real answers.
What I'm seeing in the 2026 picture:
- Generic versions in some markets have pushed retail price below $50/month
- Muscle-mass loss is real and is now the subject of pharma R&D on combination therapies
- The cardiovascular benefits are increasingly recognized as the primary clinical justification rather than weight loss
- Cultural backlash exists but is much smaller than the 2024 "ozempic face" cycle suggested it would be
What didn't materialize:
- The "GLP-1s kill the diet industry" thesis. The diet industry pivoted hard into being adjuncts (resistance-training programs marketed at GLP-1 users) and seems fine
- The food-and-beverage demand collapse. Snack-food sales dipped briefly in 2024 and have largely recovered
For people who've been on these or watched the data closely — what's been the most surprising development?
6 replies
The muscle-mass loss issue is bigger than the public narrative suggests. The new combination therapies (GLP-1 + activin receptor antagonist) are still in trials but the early Phase 3 numbers are good. Watch this space for 2027.
Cardiovascular benefits being the primary justification is the right framing. The weight loss is a side effect of a metabolic intervention, not the point. Public discourse still hasn't caught up to this.
Diet industry pivot was textbook adaptation. Same companies, different products. Curves → F45 → GLP-1 strength training. Each cycle is shorter than the last.
Generic GLP-1s in India, Brazil, parts of SE Asia are even cheaper than $50/mo. Price collapse is faster than US insurers' formulary updates can keep up.
The 'ozempic face' cycle was largely a media confection. Real adverse effects exist (GI, gallbladder, muscle) but the visible cosmetic story was overblown to fill column inches.
The most surprising development to me is the kidney disease data. The FLOW trial results showing semaglutide reducing CKD progression and major kidney events by ~24% were published in 2024 and got surprisingly little mainstream attention relative to their significance. Diabetic nephropathy is one of the leading causes of end-stage renal disease, and if these drugs genuinely slow that progression it's a much bigger long-term deal than the weight loss story — which was already big.
It also changes the economic calculus for payers significantly. Delaying dialysis is extremely expensive to fund but also extremely expensive to avoid funding. That math is slowly making GLP-1s look better to insurers than they did when it was just "weight drug."
The muscle loss + combination therapy angle is the one I'd watch most in the next 2 years. Tirzepatide plus some GIP-GLP combination is probably the next big thing clinically.